- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 479
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 5,349
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sleep, Multiple Myeloma
- Interventions
- Mindfulness Awareness Practices for Insomnia, Sleep Health Information
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Malignant Mesothelioma
- Interventions
- pemetrexed disodium, clinical observation
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 145
- States / cities
- Scottsdale, Arizona • San Francisco, California • Hartford, Connecticut + 104 more
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 35 more
- Conditions
- Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Capecitabine, Talazoparib, Pembrolizumab, Inavolisib
- Drug
- Lead sponsor
- Bryan Schneider, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 175
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more
- Conditions
- Intermittent Claudication, Ischemia Vascular, Peripheral Arterial Disease, Peripheral Vascular Disease
- Interventions
- Ischemic Preconditioning, Control Group
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Peripheral Arterial Disease
- Interventions
- Turbo Elite Laser and Turbo Tandem Laser Guide Catheters, Balloon angioplasty
- Device · Procedure
- Lead sponsor
- Spectranetics Corporation
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 28 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter, EverCross Percutaneous Transluminal Balloon Catheter
- Device
- Lead sponsor
- Spectranetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 42
- States / cities
- Yuma, Arizona • Fremont, California • Los Angeles, California + 37 more
- Conditions
- Diabetic Gastroparesis
- Interventions
- Reglan ODT
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Yoga Intervention
- Other
- Lead sponsor
- Marquette University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 40
- States / cities
- Downy, California • Fountain Valley, California • Fullerton, California + 37 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- larotaxel (XRP9881), gemcitabine, cisplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 52
- States / cities
- Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more
- Conditions
- Hypertension, Pregnancy-Induced
- Interventions
- Nifedipine ER
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Milwaukee, Wisconsin
- Conditions
- Burns
- Interventions
- Enteral Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Daren K. Heyland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Interventions
- High Dose Multivitamin, Low Dose Multivitamin
- Drug · Device
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 4,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
- Conditions
- Cardiac Toxicity, Sarcoma
- Interventions
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, conventional surgery
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 132
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 97 more
- Conditions
- Kidney Transplantation
- Interventions
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
- Conditions
- Scleroderma, Systemic
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Left Atrial Appendage Absent
- Interventions
- AtriClip
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 11
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Albany, New York + 6 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- PNK-007, Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2)
- Biological · Drug
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Hackensack, New Jersey + 4 more
- Conditions
- Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
- Interventions
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- 12 Months to 20 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 5
- States / cities
- Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 2 more
- Conditions
- Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
- Interventions
- Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more